The India construction and mining equipment market is projected to reach USD 12.4 billion by 2030, driven by large-scale infrastructure development, rising coal and mineral production, industrial corridor expansion, and the nation's target of producing 1 billion tonnes of coal annually by 2026-27

The USD 400 Million Packing Revolution, Why Travel Compression Bags Are Reshaping How America Travels

The USD 26.4 billion insulin industry is witnessing its most dramatic evolution in decades, as pharmaceutical leaders pour billions into next-generation production systems amid fierce pricing pressures driven by new government regulations and intense biosimilar competition.

The legal professionals are following the new trends in the enforcement of pharmaceutical contracts, especially with respect to the government procurement relationships that are formed in case of emergencies.

In the conceptual framework under discussion in the policy circles, the US would impose 100% tariffs on some imported patented pharmaceuticals, but there would be a vital compliance mechanism.

Dizal Pharmaceutical has reached a powerful achievement in the targeted therapy of lung cancer with remarkable results of Phase 3 clinical trial of Zegfrovy, which sets the potential game-changer of the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.

There has been tremendous consolidation behavior in the CNS therapeutic space, with a number of companies engaging in strategic acquisitions to enhance their presence in high-value neurological and psychiatric markets.

The fact that two Indian-flagged tankers of liquefied petroleum gas sailed through the Strait of Hormuz that is of much strategic importance to the world is not only a diplomatic victory but also an eye-opener as to how the world energy security is not on very solid grounds.

The pharmaceutical industry remains characterized by astounding growth direction and positioning. In this week analysis, the critical developments that are transforming the dynamics of competition, including the expansion of manufacturing capacities and modernization of the regulatory landscape

On March 6, 2026, the pharmaceutical industry has made major strategic repositioning moves in which transactions of over 4 billion dollars were announced with huge government investments in its supply chains marking a historical change in manufacturing priorities, access to its markets, and regulatory measures.